The heart-gut axis: new target for atherosclerosis and congestive heart failure therapy
- PMID: 31168383
- PMCID: PMC6519415
- DOI: 10.1136/openhrt-2018-000993
The heart-gut axis: new target for atherosclerosis and congestive heart failure therapy
Abstract
The human gut microbiota has been identified as a possible novel risk factor for cardiovascular disease. The intestinal microbiome plays a role in the pathogenesis of atherosclerosis and heart failure. Even though studies in rodents suggested that gut microbes may affect the risk of heart disease, this link has not been shown in humans. In the present study, we review several potential mechanisms by which the gut microbiome and bacterial translocation are associated with the development of cardiac disorders making them potential targets for novel therapeutic measures for these conditions. Modulation of the gut microbiota as a mechanism for altering the pathogenesis of disorders is an area of growing interest. Alteration in the gut microbiota is being explored as a method of reducing risk factors associated with cardiac diseases.
Keywords: atherosclerosis; bacterial translocation; heart failure; microbiome.
Conflict of interest statement
Competing interests: None declared.
Similar articles
-
Gut Microbiota in Cardiovascular Health and Disease.Circ Res. 2017 Mar 31;120(7):1183-1196. doi: 10.1161/CIRCRESAHA.117.309715. Circ Res. 2017. PMID: 28360349 Free PMC article. Review.
-
The Emerging Role of Gut Dysbiosis in Cardio-metabolic Risk Factors for Heart Failure.Curr Hypertens Rep. 2020 May 8;22(5):38. doi: 10.1007/s11906-020-01046-0. Curr Hypertens Rep. 2020. PMID: 32385705 Review.
-
The Gut Microbiota and Its Implication in the Development of Atherosclerosis and Related Cardiovascular Diseases.Nutrients. 2020 Feb 26;12(3):605. doi: 10.3390/nu12030605. Nutrients. 2020. PMID: 32110880 Free PMC article. Review.
-
The gut microbiome and heart failure.Curr Opin Cardiol. 2019 Mar;34(2):225-232. doi: 10.1097/HCO.0000000000000598. Curr Opin Cardiol. 2019. PMID: 30575647 Review.
-
The gut microbiome in coronary artery disease and heart failure: Current knowledge and future directions.EBioMedicine. 2020 Feb;52:102649. doi: 10.1016/j.ebiom.2020.102649. Epub 2020 Feb 12. EBioMedicine. 2020. PMID: 32062353 Free PMC article. Review.
Cited by
-
Trends in gut-heart axis and heart failure research (1993-2023): A bibliometric and visual analysis.Heliyon. 2024 Feb 7;10(4):e25995. doi: 10.1016/j.heliyon.2024.e25995. eCollection 2024 Feb 29. Heliyon. 2024. PMID: 38404792 Free PMC article.
-
Role of the intestinal microbiome and its therapeutic intervention in cardiovascular disorder.Front Immunol. 2024 Jan 26;15:1321395. doi: 10.3389/fimmu.2024.1321395. eCollection 2024. Front Immunol. 2024. PMID: 38343539 Free PMC article. Review.
-
Reduced estrogen signaling contributes to bone loss and cardiac dysfunction in interleukin-10 knockout mice.Physiol Rep. 2024 Jan;12(1):e15914. doi: 10.14814/phy2.15914. Physiol Rep. 2024. PMID: 38217044 Free PMC article.
-
Isolation, identification, and significance of salivary Veillonella spp., Prevotella spp., and Prevotella salivae in patients with inflammatory bowel disease.Front Cell Infect Microbiol. 2023 Nov 20;13:1278582. doi: 10.3389/fcimb.2023.1278582. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 38053528 Free PMC article.
-
Remote effects of kidney drug transporter OAT1 on gut microbiome composition and urate homeostasis.JCI Insight. 2023 Nov 8;8(21):e172341. doi: 10.1172/jci.insight.172341. JCI Insight. 2023. PMID: 37937647 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources